Adding Paclitaxel to Gemcitabine/Cisplatin Does Not Significantly Improve Survival in Patients with Advanced Urothelial Cancer

Share this content:

(ChemotherapyAdvisor) – Adding paclitaxel to gemcitabine/cisplatin for the treatment of patients with locally advanced or metastatic urothelial cancer demonstrated a higher response rate and a 3.1 month survival benefit vs. gemcitabine/cisplatin; however, this difference was not significant, a study in the Journal of Clinical Oncology published online February 27 has found.

Previously, a Phase I/II study had suggested that the three-drug regimen had greater antitumor activity and might improve survival. The Phase III EORTC Intergroup Study 30987 randomized patients without prior systemic therapy from 2001 to 2004 to paclitaxel/gemcitabine/cisplatin (n=312) or gemcitabine/cisplatin (n=314).

After a median follow-up of 4.6 years, median overall survival (OS), the primary outcome, was 15.8 months for paclitaxel/gemcitabine/cisplatin vs. 12.7 months for gemcitabine/cisplatin (HR=85; P=0.075). A subgroup of all eligible patients, including those with bladder primary tumors, had significantly longer OS with the 3-drug regimen, 3.2 months.

Progression-free survival was not significantly longer in the paclitaxel/gemcitabine/cisplatin arm (HR=0.87; P=0.11). Overall response rate was 55.5% in the paclitaxel/gemcitabine/cisplatin arm and 43.6% in the gemcitabine/cisplatin arm (P=0.0031). Both treatments were well tolerated; more thrombocytopenia and bleeding occurred with gemcitabine/cisplatin (11.4%) than with paclitaxel/gemcitabine/cisplatin (6.8%; P=0.05). Febrile neutropenia occurred more frequently in the paclitaxel/gemcitabine/cisplatin arm (13.2%) than in the gemcitabine/cisplatin arm (4.3%; P<0.001).

“Novel approaches will be required to obtain major improvements in survival of incurable urothelial cancer,” the investigators concluded.



Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs